Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Strong Trading Volume After Earnings Beat

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares saw strong trading volume on Tuesday after the company announced better than expected quarterly earnings. 3,152,097 shares traded hands during mid-day trading, an increase of 148% from the previous session’s volume of 1,272,675 shares.The stock last traded at $11.2350 and had previously closed at $10.88.

The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS.

Analysts Set New Price Targets

BAYRY has been the topic of several recent research reports. DZ Bank raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday. Finally, UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The company has a market capitalization of $44.15 billion, a P/E ratio of -10.12 and a beta of 0.62. The stock has a fifty day simple moving average of $11.31 and a 200-day simple moving average of $10.91. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.